Lazard Asset Management LLC Intercept Pharmaceuticals, Inc. Transaction History

Lazard Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$11.61 - $16.11 $187,594 - $260,305	-16,158 Reduced 28.25%	41,037 $507,000
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $436,544 - $704,334	35,753 Added 166.74%	57,195 $797,000
Q2 2022 Aug 09, 2022	SELL	$11.23 - $19.59 $451,142 - $786,989	-40,173 Reduced 65.2%	21,442 $296,000
Q1 2022 May 13, 2022	BUY	$13.37 - $17.79 $256,623 - $341,461	19,194 Added 45.25%	61,615 $1 Million
Q4 2021 Feb 09, 2022	BUY	$14.28 - $19.53 $605,771 - $828,482	42,421 New	42,421 $691,000
Q1 2021 May 14, 2021	SELL	$19.33 - $37.75 $147,932 - $288,900	-7,653 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$24.48 - $42.47 $171,457 - $297,459	7,004 Added 1079.2%	7,653 $189,000
Q3 2020 Nov 13, 2020	SELL	$39.09 - $53.44 $240,247 - $328,442	-6,146 Reduced 90.45%	649 $26,000
Q2 2020 Aug 13, 2020	BUY	$46.7 - $92.04 $254,001 - $500,605	5,439 Added 401.11%	6,795 $325,000
Q1 2020 May 14, 2020	BUY	$48.35 - $118.68 $65,562 - $160,930	1,356 New	1,356 $85,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.